BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 17294448)

  • 1. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck.
    Ito D; Visus C; Hoffmann TK; Balz V; Bier H; Appella E; Whiteside TL; Ferris RL; DeLeo AB
    Int J Cancer; 2007 Jun; 120(12):2618-24. PubMed ID: 17294448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
    Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
    Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants.
    Hoffmann TK; Nakano K; Elder EM; Dworacki G; Finkelstein SD; Appella E; Whiteside TL; DeLeo AB
    J Immunol; 2000 Nov; 165(10):5938-44. PubMed ID: 11067956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.
    Hoffmann TK; Donnenberg AD; Finkelstein SD; Donnenberg VS; Friebe-Hoffmann U; Myers EN; Appella E; DeLeo AB; Whiteside TL
    Cancer Res; 2002 Jun; 62(12):3521-9. PubMed ID: 12067999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 as an immunotherapeutic target in head and neck cancer.
    Hoffmann TK; Bier H; Donnenberg AD; Whiteside TL; De Leo AB
    Adv Otorhinolaryngol; 2005; 62():151-60. PubMed ID: 15608425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
    Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
    Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck.
    Visus C; Ito D; Amoscato A; Maciejewska-Franczak M; Abdelsalem A; Dhir R; Shin DM; Donnenberg VS; Whiteside TL; DeLeo AB
    Cancer Res; 2007 Nov; 67(21):10538-45. PubMed ID: 17974998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide.
    Röpke M; Hald J; Guldberg P; Zeuthen J; Nørgaard L; Fugger L; Svejgaard A; Van der Burg S; Nijman HW; Melief CJ; Claesson MH
    Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14704-7. PubMed ID: 8962118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.
    Umano Y; Tsunoda T; Tanaka H; Matsuda K; Yamaue H; Tanimura H
    Br J Cancer; 2001 Apr; 84(8):1052-7. PubMed ID: 11308253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant.
    McArdle SE; Rees RC; Mulcahy KA; Saba J; McIntyre CA; Murray AK
    Cancer Immunol Immunother; 2000 Oct; 49(8):417-25. PubMed ID: 11043848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma.
    Cicinnati VR; Zhang X; Yu Z; Ferencik S; Schmitz KJ; Dworacki G; Kaczmarek E; Oldhafer K; Frilling A; Baba HA; Schmid KW; Grosse-Wilde H; Broelsch CE; DeLeo AB; Gerken G; Beckebaum S
    Int J Cancer; 2006 Dec; 119(12):2851-60. PubMed ID: 16998881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides.
    Sakakura K; Chikamatsu K; Furuya N; Appella E; Whiteside TL; Deleo AB
    Clin Immunol; 2007 Oct; 125(1):43-51. PubMed ID: 17631051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules.
    Gnjatic S; Bressac-de Paillerets B; Guillet JG; Choppin J
    Eur J Immunol; 1995 Jun; 25(6):1638-42. PubMed ID: 7542198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ T helper responses in squamous cell carcinoma of the head and neck.
    Chikamatsu K; Sakakura K; Yamamoto T; Furuya N; Whiteside TL; Masuyama K
    Oral Oncol; 2008 Sep; 44(9):870-7. PubMed ID: 18221909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein.
    Barfoed AM; Petersen TR; Kirkin AF; Thor Straten P; Claesson MH; Zeuthen J
    Scand J Immunol; 2000 Feb; 51(2):128-33. PubMed ID: 10652158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells.
    Chikamatsu K; Nakano K; Storkus WJ; Appella E; Lotze MT; Whiteside TL; DeLeo AB
    Clin Cancer Res; 1999 Jun; 5(6):1281-8. PubMed ID: 10389910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope.
    Würtzen PA; Claesson MH
    Int J Cancer; 2002 Jun; 99(4):568-72. PubMed ID: 11992547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD8+ T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck.
    Andrade Filho PA; Ito D; Deleo AB; Ferris RL
    Cancer Immunol Immunother; 2010 Oct; 59(10):1561-8. PubMed ID: 20577877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
    Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
    Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.